• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Nascent Biotech News

antibody-600
Nascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

Nascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

May 4, 2022  Corporate News, News

VERO BEACH, FL / ACCESSWIRE / May 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology [...]

0
Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

April 12, 2022  News, Press Releases
The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial

The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial

March 8, 2022  Science News
Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical

Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical

February 23, 2022  Corporate News
Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial

Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial

January 11, 2022  Corporate News, Press Releases, Science News
Load More

Delivering human antibodies for the treatment of cancer

© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.